Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP EBITDA Margin
EBITDA as a percentage of revenue.
Coeptis Therapeutics, Inc.NASDAQ: COEP
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -3081.3%
EBITDA Margin was -3081.3% in Q1 FY2026, up 1760.4 pp from a year earlier. On a trailing-twelve-month basis it was -769.0%, up 15034.6 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 20.0% for the fiscal year ending Dec 2026, up from -763.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -3081.3%-2979.6 pp QoQ
- Last fiscal yearDec 2025
- -763.9%— YoY
- LTMMar 2026
- -769.0%+15034.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1760.4 pp | +1993.9 pp | +233.6 pp |
| 1 year | — | +783.9 pp | — |
| 3 years | — | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -763.9%
- Year-over-year change
- —
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -763.9% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | -17086.3% | — |
EBITDA Margin vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 EBITDA Margin of -769.0% is the 4th highest of the 6 companies compared; the peer median is -97.9%.
- Its year-over-year change of +15034.6 pp is the highest of 5, against a peer median of +166.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 3.2% | +1695.0 pp | +2334.4 pp | |
| LTM Mar 2026 | -48.4% | +416.8 pp | +3974.4 pp | |
| LTM Mar 2026 | -97.9% | -84.1 pp | -13.9 pp | |
| LTM Mar 2026 | -769.0% | +15034.6 pp | — | |
| LTM Mar 2026 | -1017.5% | — | — | |
| LTM Mar 2026 | -18634.1% | -28166.9 pp | — | |
| FY2025 | — | — | — | |
OSTXOS Therapies Incorporated | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding COEP) | -97.9% | +166.4 pp | +2334.4 pp | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75K | 0 | 0 | 0 | 1.36M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 180.63K |
| Gross Profit | 75K | 0 | 0 | 0 | 1.18M |
| Gross Margin | 100.0% | — | — | — | 86.7% |
| Research & Development | 0 | 20.89K | 6.67M | 2.33M | 1.28M |
| Selling, General & Admin | 14.12M | 34.18M | 13.82M | 6.72M | 11.95M |
| Operating Expenses | 14.12M | 34.2M | 21.49M | 10.05M | 14.23M |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| EBITDA | (12.81M) | (36.35M) | (20.12M) | (9.38M) | (10.41M) |
| EBITDA Margin | -17086.3% | — | — | — | -763.9% |
| Operating Income | (14.05M) | (34.2M) | (21.49M) | (10.05M) | (13.04M) |
| Operating Margin | -18727.9% | — | — | — | -956.9% |
| Interest Income | 0 | 0 | 0 | 0 | 116.5K |
| Interest Expense | 187.13K | 218.41K | 107.69K | 396.12K | 642.38K |
| Other Income / Expenses | 596.65K | (3.38M) | 224.59K | (822.92K) | 766.31K |
| Income Before Tax | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (12.28M) |
| Pre-Tax Margin | -17932.4% | — | — | — | -900.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.68M) | (11.92M) |
| Net Margin | -17932.4% | — | — | — | -874.3% |
| EPS (Basic) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| EPS (Diluted) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| Weighted Avg Shares | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
| Weighted Avg Shares (Diluted) | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.